1,357
Views
12
CrossRef citations to date
0
Altmetric
Review

European Vaccine Initiative: lessons from developing malaria vaccines

, , , , , , , & show all
Pages 1697-1708 | Published online: 09 Jan 2014

References

  • Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet373(9674), 1570–1575 (2009).
  • Breman JG, Egan A, Keusch GT. The intolerable burden of malaria: a new look at the numbers. Am. J. Trop. Med. Hyg.64(Suppl. 1–2), iv–vii (2001).
  • Roca-Feltrer A, Carneiro I, Armstrong Schellenberg JR. Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years. Trop. Med. Int. Health13(6), 771–783 (2008).
  • Thwing J, Eisele TP, Steketee RW. Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the lives saved tool. BMC Pub. Health11(Suppl. 3), S14 (2011).
  • O’Meara WP, Bejon P, Mwangi TW et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet372(9649), 1555–1562 (2008).
  • A research agenda for malaria eradication: vaccines. PLoS Med.8(1), e1000398 (2011).
  • Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366(9502), 2012–2018 (2005).
  • Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccines6(1), 90–96 (2010).
  • Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev. Vaccines10(5), 589–599 (2011).
  • Greenwood B, Targett G. The mysteries of immunity to malaria. Lancet377(9779), 1729–1730 (2011).
  • Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J. Clin. Invest.120(12), 4168–4178 (2010).
  • Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin. Microbiol. Rev.22(1), 13–36 (2009).
  • Imoukhuede EB, Ventura R, Imbault N, Van Schooten H, Leroy O. European Malaria vaccine initiative: portfolio and perspectives for the future. Hum. Vaccin.6(1), 146–150 (2009).
  • Roestenberg M, Remarque E, De Jonge E et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One3(12), e3960 (2008).
  • Osier FH, Weedall GD, Verra F et al. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect. Immun.78(11), 4625–4633 (2010).
  • Ouattara A, Mu J, Takala-Harrison S et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar. J.9, 175 (2010).
  • Theisen M, Soe S, Brunstedt K et al. A Plasmodium falciparum GLURP–MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine22(9–10), 1188–1198 (2004).
  • Esen M, Kremsner PG, Schleucher R et al. Safety and immunogenicity of GMZ2 – a MSP3–GLURP fusion protein malaria vaccine candidate. Vaccine27(49), 6862–6868 (2009).
  • Mordmuller B, Szywon K, Greutelaers B et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine28(41), 6698–6703 (2010).
  • Porter DW TF, Berthoud TK, Hutchings CL et al. A human Phase 1/2a malaria challenge trial of a polyprotein malaria vaccine. Vaccine29(43), 7514–7522 (2011).
  • Olugbile S, Habel C, Servis C, Spertini F, Verdini A, Corradin G. Malaria vaccines – the long synthetic peptide approach: technical and conceptual advancements. Curr. Opin. Mol. Ther.12(1), 64–76 (2010).
  • Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med.365(11), 1062–1064 (2011).
  • Sirima SB, Tiono AB, Ouedraogo A et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12–24 months-old Burkinabe children. PLoS One4(10), e7549 (2009).
  • Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol.24(2), 74–84 (2008).
  • Craig AG, Holder AA, Leroy OY, Ventura RA. Malaria vaccines – how and when to proceed? Trends Parasitol.25(12), 535–537 (2009).
  • Villard V, Agak GW, Frank G et al. Rapid identification of malaria vaccine candidates based on α-helical coiled coil protein motif. PLoS One2(7), e645 (2007).
  • Olugbile S, Villard V, Bertholet S et al. Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope. Vaccine29(40), 7090–7099 (2011).
  • Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine25(5), 806–813 (2007).
  • Richards JS, Stanisic DI, Fowkes FJ et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis.51(8), e50–e60 (2010).
  • Hill AV, Reyes-Sandoval A, O’Hara G et al. Prime–boost vectored malaria vaccines: progress and prospects. Hum. Vaccin.6(1), 78–83 (2010).
  • Reyes-Sandoval A, Sridhar S, Berthoud T et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol.38(3), 732–741 (2008).
  • Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J.8, 312 (2009).
  • Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun.74(10), 5933–5942 (2006).
  • Sheehy SH, Duncan CJ, Elias SC et al. Phase 1a clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. doi:10.1038/mt.2011.176 (2011) (Epub ahead of print).
  • O’Hara GA, Duncan CJA, Ewer KJ et al. Clinical assessment of a recombinant simian adenovirus chad63: a potent new vaccine vector. J. Infect. Dis. (2011) (In Press).
  • Moorthy VS, Kieny MP. Reducing empiricism in malaria vaccine design. Lancet Infect. Dis.10(3), 204–211 (2010).
  • Cavanagh DR, Dubois PM, Holtel A et al. Towards validated assays for key immunological outcomes in malaria vaccine development. Vaccine29(17), 3093–3095 (2011).
  • Kisser A, Heininger U, Moorthy VS, Akanmori BD, Leroy O. Addressing the needs and gaps in safety assessment of vaccines during clinical trials in resource limited countries. Vaccine29(24), 4173–4174 (2011).
  • Thogersen RL, Holder AA, Hill AV, Arnot DE, Imoukhuede EB, Leroy O. Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field? Malar. J.10(1), 255 (2011).
  • Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis.11(2), 102–109 (2011).
  • Roestenberg M, Mccall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med.361(5), 468–477 (2009).
  • Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature433(7022), 164–167 (2005).
  • Epstein JE, Tewari K, Lyke KE et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science334(6055), 475–480 (2011).
  • Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccin.6(1), 107–113 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.